[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Albany Medical College\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":273},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,46,71,100,136,166,193,220,242],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100644616","phase-2-pilot-randomized-control-trial-comparing-oral-ketamine-and-oral-oxycodone-for-pain-control-in-emergency-department-patients-100644616",false,"NCT07670507","Pilot Randomized Control Trial Comparing Oral Ketamine and Oral Oxycodone for Pain Control in Emergency Department Patients","PKORCT","Inclusion Criteria:\n\n* ED patient aged 18 years or older AND\n* English proficient AND\n* Able to give informed consent AND\n* Has a painful condition in the ED that includes any of the following: Musculoskeletal extremity pain, Musculoskeletal back or neck pain, Other nociceptive extremity pain\n* AND treating provider has deemed the patient necessitating 'second line pain therapy' (meaning: opioids or ketamine)\n\nExclusion Criteria:\n\nAny of the following:\n\n* Prisoner status\n* Pregnant\n* Non-English proficient\n* Cannot give informed consent\n* Requires emergent intravenous pain medicine (as deemed by the treating provider)\n* Prior participation in the study\n* Previous diagnosis of opioid use disorder\n* Previous ketamine addiction\n* Patient is in hospice or other palliative care measures\n* Contraindication to ketamine, including: Cystitis or bladder pain, Intracranial hypertension, Known coronary artery disease, Age greater than 75 years old, History of prior adverse reaction to ketamine or oxycodone, History or current major psychiatric disorder (as deemed by the treating ED clinician) or history of psychosis","ALL","18 Years","75 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE2","PHASE3","The goal of this pilot randomized clinical trial is to learn if oral ketamine intervention can control pain in emergency department patients whose providers feel the need for additional pain medication. The main questions it aims to answer are:\n\n* Does oral ketamine result in a different mean change in pain scores compared with oral oxycodone?\n* Is there a difference in the need for additional opioid administration within 24 hours after the initial dose of study medication (oral ketamine vs oral oxycodone)?\n\nResearchers will compare oral ketamine to oral oxycodone to see if there is a difference in pain control or the need for additional opioid administration.\n\nParticipants will:\n\n* Fill out a survey prior to study medication administration assessing pain scores, pain presentation, and medication history\n* Be randomized to and receive a dose of oral ketamine or oral oxycodone as the study medication for pain control\n* Fill out a survey assessing pain control, side effects, and safety outcomes\n* Receive follow-up phone calls at 1 and 3 months after enrollment to assess pain and opioid use",[28],"Pain Management",[30,31,32],"oral ketamine","pain control","oxycodone","NOT_YET_RECRUITING","2026-06-22",{"date":36,"type":37},"2026-06-26","ACTUAL",{"date":39,"type":21},"2026-06-24",{"date":41,"type":21},"2027-04-30",{"name":43,"class":44},"Albany Medical College","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":53,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":4},"100636756","effect-of-vibrator-use-on-symptoms-of-urgency-urinary-incontinence-sexual-function-and-sleep-100636756","NCT07569822","Effect of Vibrator Use on Symptoms of Urgency Urinary Incontinence, Sexual Function, and Sleep","BLISS","Inclusion Criteria:\n\n* Assigned female at birth.\n* Age ≥18 years.\n* Able to read and speak English.\n* Diagnosis of urgency urinary incontinence or mixed urinary incontinence (based on clinical assessment and UDI-6 urgency questions).\n* Leaks urine at least once per week due to urgency.\n* Postvoid residual volume \\\u003C100 mL or a third of the voided volume\n\nExclusion Criteria:\n\n* Pelvic organ prolapse beyond the hymen\n* Neurogenic bladder, multiple sclerosis, or other neurologic causes of incontinence.\n* Recurrent urinary tract infection (\\>3 UTIs in the past year or \\>2 in the past 6 months).\n* Active urinary tract infection at the time of enrollment.\n* Interstitial cystitis\u002Fbladder pain syndrome.\n* Current use of sacral neuromodulation or percutaneous tibial nerve stimulation (PTNS).\n* Bladder Botox injection within the past 6 months.\n* Vibrator use within the past 3 months.\n* Patients uncomfortable with vibrator use\n* Pregnancy or plans for pregnancy during the study period.","FEMALE",{"count":55,"type":21},116,[57],"NA","This study aims to understand if using a vibrator affects urgency related urinary incontinence. Insights from this study may open new recommendations for treating urinary urgency and incontinence.",[60],"Urgency Urinary Symptoms",[62],"incontinence","2026-04-29",{"date":65,"type":37},"2026-05-06",{"date":67,"type":21},"2026-07-01",{"date":69,"type":21},"2028-06-30",{"name":43,"class":44},{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":81,"briefSummary":82,"conditions":83,"keywords":86,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":45},"100625186","drain-drainage-in-acute-decompensated-heart-failure-with-pleural-effusions-100625186","NCT07419360","DRAIN: DRainage in Acute Decompensated Heart faIlure With Pleural effusioNs","Role of Therapeutic Thoracentesis in Hospitalized Patients With Acute Decompensated Heart Failure: Randomized Controlled Trial","DRAIN-IT","Inclusion Criteria:\n\n* Adult patients age \\>18 years and.\n* Clinical diagnosis of acute decompensated heart failure with at least one clinical sign of volume overload (e.g., peripheral edema, pleural effusion, or ascites) and\n* Assessment of left ventricular ejection fraction (LVEF) by echocardiography performed during the time of index hospitalization or within 3 months prior to enrollment and\n* Serum NT-proBNP level of \\>1000 pg\u002Fml or Serum BNP\\>250 pg\u002Fml at the time of enrollment and\n* Radiographic evidence of moderate to large pleural effusion, defined as pleural fluid occupying more than 1\u002F3rd of the hemithorax on chest X-ray.\n\nExclusion Criteria:\n\n* Clinical indication for diagnostic thoracentesis - Presence of fever, clinical signs of infection, or atypical pleural effusion for CHF (unilateral left-sided effusion, findings suggestive of malignancy, infection, or alternative etiologies) or.\n* Loculated pleural effusion - Evidence of loculated pleural effusion on thoracic ultrasound, as defined as the presence of septations or complex homogenous echogenic fluid (see Imaging Assessment section) or.\n* Clinical indication for therapeutic thoracentesis - Presence of massive pleural effusion with acute respiratory failure requiring positive pressure ventilation, high-flow oxygen therapy (\\>15 liters per minute of flow), or tension hydrothorax (massive effusion with mediastinal shift and hemodynamic compromise) or.\n* Contraindication to thoracentesis, uncontrolled bleeding diathesis, or irreversible INR \\> 2.0 and platelet count \\\u003C50,000 or.\n* Patient with mechanical mitral valve, where anticoagulation cannot be safely held or.\n* Pleural procedure, such as but not limited to thoracentesis, chest tube placement, or thoracoscopy, within 3 months prior to enrollment or.\n* Cardiac or thoracic surgery within 3 months prior to enrollment or.\n* Requirement for chronic renal replacement therapy, such as hemodialysis or peritoneal dialysis or.\n* Pregnancy or\n* Inability or unwillingness to provide informed consent, or current incarceration (prisoners).",{"count":80,"type":21},216,[57],"The goal of this study is to assess if removal of fluid around the lungs (pleural effusion) by a routine procedure called as thoracentesis is helpful to decrease shortness of breath in hospitalized patients with congestive heart failure and have pleural effusion.\n\nResearchers will compare thoracentesis with medical therapy to medical therapy alone to see if one treatment is superior to the other treatment in relieving shortness of breath.\n\nParticipants will :\n\n1. Receive medical therapy with or without thoracentesis\n2. Record degree of shortness of breath and quality of life before and after the intervention using predefined standard scales.\n3. Telephonic call for 15- 30 mins at day 14 and 30 after enrollment to assess shortness of breath and quality of life",[84,85],"Congestive Heart Failure(CHF)","Pleural Effusion Due to Congestive Heart Failure",[87,88,89,90],"congestive heart failure","pleural effusion","dyspnea","hospital length of stay","RECRUITING","2026-04-24",{"date":94,"type":37},"2026-04-30",{"date":96,"type":37},"2026-02-15",{"date":98,"type":21},"2029-06",{"name":43,"class":44},{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":110,"conditions":111,"keywords":116,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":45},"100567482","single-lumen-midline-catheter-vs-long-peripheral-intravenous-cather-for-difficult-intravenous-access-in-the-ed-100567482","NCT06668766","Single Lumen Midline Catheter vs Long Peripheral Intravenous Cather for Difficult Intravenous Access in the ED","Superior Ultrasound-Guided Venous Access: Single-Lumen Midline Catheters vs Long Peripheral IVs for Difficult IV Access in the Emergency Department, A Randomized Controlled Trial","Inclusion Criteria:\n\n* Adult (age 18 and older) patients presenting to the AMC ED with difficult IV access defined as any of the following:\n\n  * Two failed attempts at landmark based IV or US-guided peripheral vascular access by qualified ED staff\n  * Self-reported history of difficult IV access and one of the following:\n\n    * History of requiring 2 or more IV attempts on a previous visit (either self-reported or documented in the electronic medical record)\n    * Previous requirement for a rescue device after failed IV access attempt. These devices are as follows:\n* US guided PIV\n* Midline catheter\n* Peripherally inserted central catheter\n* Central venous catheter\n* Intraosseous catheter\n* History of or active comorbid disease state with known difficult IV access\n* Prior or current implanted port device\n* End stage renal disease with fistula\n* Sickle cell disease\n* History of or active intravenous drug use\n\nExclusion Criteria:\n\n* Patients under the age of 18\n* Known Prisoners\n* Non-English-speaking patients\n* Patients in whom the device cannot be stabilized due to tissue or treatments in bilateral extremities or available extremity (burns, complex humeral fractures, dialysis fistulas etc.)\n* Patients lacking capacity to consent\n* Patients unable to sign written consent\n* Patients without identifiable target veins by ultrasonography\n* Known pregnant patients\n* Previously enrolled in this study\n* Previously withdrawn from this study\n* Presented when no study IV proceduralists are available\n* Patients in whom obtaining informed consent and being enrolled in the study would put them at risk for obtaining time sensitive medical care",{"count":108,"type":21},270,[57],"Many patients in the emergency department have veins that are difficult to get an intrevenous (IV) catheter into (called \"difficult IV access\"). These patients may require other methods to obtain access to a vein for administration of the necessary medications. The 2-inch long IV is most commonly used in emergency departments for people with difficulty IV access. Typically, a healthcare worker will use an ultrasound to help to see the veins underneath the skin while inserting the IV into the vein. That is, the ultrasound helps the healthcare worker visualize veins that are deeper in the arm and may not be felt through the skin. Another device that can be used is a 4-inch midline catheter. This device is less commonly used as many emergency departments do not have participants available, but it serves the same purpose as the 2-inch long IVs (that is, to give medicine into the vein and sometimes to take blood). A 4-inch midline catheter is similar to a 2-inch long IV, but has a few differences. First, the 4-inch midline catheter is even longer than the 2-inch long IV. The 4-inch midline catheter is 10-cm (about 4-inches or the size of 4 quarters side-by-side), while the 2-inch long IV is 4.78-cm (nearly 2-inches or two quarters side-by-side). Second, the 4-inch midline catheter is inserted into using a guidewire to help move the catheter in the vein (similar in concept to a train moving along a track), while the 2-inch long IV does not have this guidewire. The guidewire does not hurt and most do not know it is being used. It is just an additional step to help guide the catheter in the vein. The investigators are conducting this research study to determine which catheter is better for patients with difficult IV access: the 4-inch midline catheter or the 2-inch long IV.",[112,113,114,115],"Difficult Intravenous Access","Midline Catheter","Peripheral Intravenous Catheter","Emergency Department Patient",[117,118,119,120,121,122,123,124,125,126,127],"midline catheter","difficult intravenous access","difficult IV access","USGIV","long peripheral IV","peripheral IV","peripheral intravenous catheter","Emergency department","emergency medicine","single lumen midline catheter","long peripheral intravenous catheter","2026-01-16",{"date":130,"type":37},"2026-01-20",{"date":132,"type":37},"2025-01-01",{"date":134,"type":21},"2027-10-21",{"name":43,"class":44},{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":144,"minAge":17,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":22,"phases":147,"briefSummary":148,"conditions":149,"keywords":152,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":165},"100555885","fusion-or-cognitive-ultrasound-guided-biopsy-to-detect-prostate-cancer-100555885","NCT06517901","Fusion or Cognitive Ultrasound-guided Biopsy to Detect Prostate Cancer","MRI-targeted Fusion or Cognitive Ultrasound-guided Biopsy to Detect Prostate Cancer","FOCUS-PC","Inclusion Criteria:\n\n* Men undergoing prostate biopsy (either transrectal or transperineal) for suspected prostate cancer as part of their regular medical care\n* Must be eligible to undergo both prostate biopsy procedure (cognitive or fusion)\n* Men undergoing their first prostate biopsy procedure or with no previous prostate biopsy within 3 years\n* Pre-biopsy mp-MRI of prostate with one or more lesions classified as PIRADS 3-5\n* Largest dimension of any lesion on mp-MRI to be ≤ 2 cm\n* Prostate-specific antigen level ≤ 20 ng\u002FmL and\u002For abnormal digital rectal examination\n\nExclusion Criteria:\n\n* mp-MRI detected lesions that are \\> 2 cm\n* History of prostate biopsy within 3 years\n* Previous diagnosis of prostate cancer\n* Contraindications to prostate biopsy (eg, fever, evidence of genito-urinary infection, excessive co-morbidities as per treating physician)","MALE",{"count":146,"type":21},1306,[57],"The MRI-targeted biopsy for prostate cancer detection can be performed using one of two techniques:\n\n1. Software-based fusion of MRI and ultrasound images (software fusion) or\n2. Visually estimated MRI-informed (cognitive fusion) technique\n\nTo date, there is a lack of adequately powered RCTs directly comparing the cognitive vs fusion targeted biopsy. This randomized study will directly compare the detection rates of clinically significant prostate cancer following either the cognitive or the fusion targeted prostate biopsy in men with suspicious lesions noted on multi-parametric MRI (mp-MRI) of prostate.",[150,151],"Prostate Cancer","Diagnosis",[153,154,155,151,156],"Prostate","Cancer","Biopsy","MRI","2025-09-30",{"date":159,"type":37},"2025-10-03",{"date":161,"type":37},"2025-04-18",{"date":163,"type":21},"2027-06-30",{"name":43,"class":44},4,{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":16,"minAge":173,"maxAge":174,"enrollmentInfo":175,"targetDuration":4,"studyType":22,"phases":177,"briefSummary":178,"conditions":179,"keywords":182,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":45},"100526482","optimal-pulse-width-used-in-transcutaneous-electrical-nerve-stimulation-for-treating-nocturnal-enuresis-in-children-100526482","NCT06135311","Optimal Pulse Width Used in Transcutaneous Electrical Nerve Stimulation for Treating Nocturnal Enuresis in Children","Optimal Pulse Width Used in Transcutaneous Electrical Nerve Stimulation (TENS) for Treating Nocturnal Enuresis in Children","Inclusion Criteria:\n\n1. Presenting with nocturnal enuresis (more than 1x a week)\n2. Failed Behavioral modification treatment (limiting evening drinking, double voiding prior to bedtime, bowel habits, social anxiety factors) during the 30 day period prior to randomization\n3. Ability to provide informed consent and assent and complete study requirements\n\nExclusion Criteria:\n\n1. Patients who have previously tried pharmacologic treatment for nocturnal enuresis, neuromodulation or other alternative therapy for urologic disorders within the past 30 days\n2. Daytime incontinence symptoms\n3. Known \"high volume\" voiders (determined from history)\n4. Bedwetting episodes on the average of less than two times per week,\n5. Medications predisposing to incontinence (eg, Lithium for bipolar disorder)\n6. Other known voiding or neurologic disorders (eg, overactive bladder, myelomeningocele, interstitial cystitis, etc)\n7. Secondary etiologies for nocturnal enuresis (eg, cystitis, obstructive sleep apnea, urinary fistulae, heart disease)\n8. Any contraindications to usage of a TENS unit (pacemaker or other implantable device, lymphedema, pregnancy, malignancy, bleeding or clotting disorders, unhealthy tissue, seizure disorders, impaired cognition)\n9. Any history of heart disease or complications","5 Years","17 Years",{"count":176,"type":21},70,[57],"Children referred to pediatric urology clinic for primary nocturnal enuresis will be screened for enrollment. Patients who fail will next be offered therapy with a bedwetting alarm device or a TENS unit as an alternative, and those who chose TENS therapy will be included in the study.The patients will be randomized into two groups of 35 patients each.Group 1 will be the high pulse width set at 260us. Group 2 will be the low pulse width set at 50us. The patients will be provided with a TENS unit and electrode pads and caretakers instructed on how to use the apparatus. The child's TENS unit will be set at a pulse width determined by randomization, frequency of 10Hz, and an intensity to be determined in the office based upon when the child feels sensitive to the TENS unit. The child will be randomized and will place the electrodes along the posterior tibial nerve on the medial ankle each night before bed time for 30 minutes for a total of 30 days. Diaries including nighttime incontinence episodes and a \"wet sheet\" scale (dry, damp, wet, soaked) will be recorded, along with any adverse reactions to the TENS unit. Patients will be followed up after one month of TENS with evaluation including the Bowel \\& Bladder Questionnaire (BBQ), a validated tool for measuring symptoms in children with voiding dysfunction \\[6\\]; this questionnaire will be filled out prior to starting TENS treatment in order to compare the effect of treatment. The data will be collected at different time points (baseline and after 1 month of treatment) for each group by itself and the groups compared against each other using statistical analysis.",[180,181],"Nocturnal Enuresis","Bedwetting",[183,181,184],"Noctural Eneuresis","TENS","2025-09-29",{"date":187,"type":37},"2025-10-02",{"date":189,"type":37},"2023-10-24",{"date":191,"type":21},"2026-12-31",{"name":43,"class":44},{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":53,"minAge":17,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":22,"phases":202,"briefSummary":203,"conditions":204,"keywords":210,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":217,"leadSponsor":219,"locationsCount":45},"100576803","impact-of-patient-selected-visual-art-in-the-hospital-room-during-antepartum-admission-on-hospital-satisfaction-scores-and-patient-experience-100576803","NCT06790043","Impact of Patient Selected Visual Art in the Hospital Room During Antepartum Admission on Hospital Satisfaction Scores and Patient Experience","Randomized Control Trial: Impact of Patient Selected Visual Art in the Hospital Room During Antepartum Admission on Hospital Satisfaction Scores and Patient Experience.","Inclusion Criteria:\n\n* patients who are greater than or equal to 18 years of age\n* patients admitted to the study hospital's antepartum unit for care\n* currently pregnant\n* willing and able to provide informed consent and complete the provided questionnaire\n\nExclusion Criteria:\n\n* patients less than 18 years of age\n* patients who are not pregnant\n* patients who are not admitted to study hospital's antepartum unit\n* patients who cannot provide informed consent in English\n* patients who have participated in this study during a previous admission",{"count":201,"type":21},100,[57],"The purpose of this study is to assess whether patient-selected visual art for patients admitted to the antepartum unit will increase hospital satisfaction compared to routine care.",[205,206,207,208,209],"Pregnancy","Pregnancy Complications","Hospital Environment","Hospitalization","Satisfaction, Patient",[211,212],"Visual Art","Antepartum Hospitalization","2025-02-18",{"date":215,"type":37},"2025-02-19",{"date":132,"type":37},{"date":218,"type":21},"2026-12",{"name":43,"class":44},{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":224,"acronym":4,"eligibilityCriteria":225,"healthyVolunteers":11,"sex":53,"minAge":17,"maxAge":4,"enrollmentInfo":226,"targetDuration":4,"studyType":22,"phases":228,"briefSummary":229,"conditions":230,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":45},"100568155","vibrator-use-to-improve-sexual-and-pelvic-floor-function-among-urogynecology-patients-100568155","NCT06677541","Vibrator Use to Improve Sexual and Pelvic Floor Function Among Urogynecology Patients","Inclusion Criteria:\n\n* • Women aged 18 and over presenting to the urogynecology clinic.\n\n  * Women diagnosed with one of the following urogynecologic conditions\n\n    o Pelvic organ prolapse, urgency incontinence, overactive bladder, stress urinary incontinence, fecal incontinence, recovering from a urogynecologic surgery over 6 weeks following surgery and clear for intercourse. Patients post op who continue to have pelvic floor dysfunction can be candidates for the study if they continue to have one of the pelvic floor dysfunctions listed.\n  * Patient will be screened with the FSFI and will be eligible if they score less than 26.55\n  * Patient's must be willing to use a vibrator.\n  * Able to provide informed consent.\n  * Not currently using a vibrator or has not used a vibrator in the past 3 months.\n  * Able to read and write in English\n\nExclusion Criteria:\n\n* • Patients with cognitive impairment.\n\n  * Patients with refusal or discomfort with vibrator use.\n  * Currently using a vibrator or has used a vibrator in the past 3 months.\n  * Patients unable to provide informed consent.\n  * Patients not clear for intercourse following their surgery\n  * Patients with surgery within 2 months of recruitment.",{"count":227,"type":21},84,[57],"Limited data exist describing the use and role of vibrators in a urogynecology population and no randomized controlled trials investigating the use of vibrators as a therapeutic tool to enhance sexual and pelvic floor function in urogynecology patients has been conducted. This study aims to evaluate the efficacy of vibrator use in improving sexual and pelvic floor function in urogynecology patients who report sexual dysfunction.",[231,232,233],"Pelvic Floor Dysfunction","Sexual Dysfunction Female","Vibrator","2025-01-14",{"date":236,"type":37},"2025-01-15",{"date":238,"type":37},"2024-11-01",{"date":240,"type":21},"2026-01-31",{"name":43,"class":44},{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":248,"eligibilityCriteria":249,"healthyVolunteers":11,"sex":144,"minAge":17,"maxAge":250,"enrollmentInfo":251,"targetDuration":4,"studyType":22,"phases":253,"briefSummary":255,"conditions":256,"keywords":259,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":272},"100487623","phase-4-anti-inflammatory-drugs-and-serum-prostate-specific-antigen-test-100487623","NCT05629494","Anti-inflammatory Drugs and Serum Prostate-Specific Antigen Test","Effect of Non-steroidal Anti-inflammatory Drugs on Serum Prostate Specific Antigen Level","ADAPT-PSA","Inclusion Criteria:\n\n* Male patients age between 18-80 years old with a screening PSA \\> 3 ng\u002Fml being considered for additional diagnostic testing (e.g., MRI, biopsy)\n* Normal digital rectal examination within the past two years. A documented normal digital rectal examination by another physician or advanced practice provider (NP, PA, etc) is acceptable.\n* No clinical symptoms concerning for acute urinary tract infection (e.g. dysuria, malodorous urine, positive urine culture)\n\nExclusion Criteria:\n\n* History of hypersensitivity or allergy to ibuprofen or NSAIDs.\n* History of peptic ulcer disease, GI bleeding or NSAIDs induced GI adverse events\n* Known bleeding disorders\n* Known severe chronic kidney disease: eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m2\n* Heart failure, significant heart disease\n* Poorly controlled hypertension\n* Active urinary tract infections or bacteriuria\n* Concomitant use of 5-alpha reductase inhibitors (finasteride, dutasteride) unless patient has been taking it for at least 6 months\n* Known prostate cancer or underwent prostate MRI or biopsy in the last year\n* Urinary tract instrumentation in the past 6 weeks (catheter, cystoscopy)\n* Concomitant anti-inflammatory or steroidal drugs\n* Concomitant dual-antiplatelet or anticoagulant therapy use except aspirin 81 mg alone\n* Know history of severe liver disease determined by abnormal liver function tests (elevated AST or ALT \\> 3X ULN based on exiting history or labs)\n* Any other medical contraindication to NSAIDs","80 Years",{"count":252,"type":21},198,[254],"PHASE4","Prostate cancer is the most frequently diagnosed cancer in men in the Unites States. Nearly 1 million prostate biopsy procedures are performed in the United States annually and elevated prostate-specific antigen (PSA) level is the primary reason for prostate biopsy in \\> 90% of cases. However, at the PSA levels which trigger prostate biopsy, often no cancer is found in prostate biopsy specimens. PSA test can be elevated due to reasons other than cancer such as inflammation or natural variation in the level. Investigators plan to treat men with elevated PSA level with over the counter anti-inflammatory medications (ibuprofen, naproxen) to see if the PSA level will decrease to an acceptable level.",[150,257,258],"Prostate Inflammation","PSA",[260,261,262,263],"Prostate-specific antigen","PSA test","Prostate biopsy","non-steroidal anti-inflammatory drugs NSAIDS","2024-10-17",{"date":266,"type":37},"2024-10-18",{"date":268,"type":37},"2022-09-27",{"date":270,"type":21},"2026-12-01",{"name":43,"class":44},3,""]